InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
NanoViricides, Inc. (NYSE American: NNVC) announced it is awaiting regulatory approval to begin a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus in the Democratic Republic of the Congo after submitting an application to the local regulatory agency. The company said it has secured financing to support the study, which is designed to evaluate the oral antiviral in…